½ÃÀ庸°í¼­
»óǰÄÚµå
1820320

¿ä°ü ½ºÅÙÆ® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : Á¦Ç° À¯Çüº°, Àç·áº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2025-2033³â)

Ureteral Stents Market Size, Share, Trends and Forecast by Product Type, Material, Application, End Use, and Region, 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¿ä°ü ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â 2024³â 3¾ï 9,552¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 6¾ï 1,922¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 5.06%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 36.9% ÀÌ»óÀÇ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ºñ´¢±â°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, ½ºÅÙÆ® ±â¼úÀÇ »õ·Î¿î ±â¼ú ¹ßÀü, ¿ä°ü ½ºÅÙÆ® äÅÃÀ» Àå·ÁÇÏ´Â À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥ÀÇ ½ÃÇàÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

¿ä°ü ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº ½ÅÀå Áúȯ, ƯÈ÷ ¿ä·Î Àå¾Ö ¹× ½ÅÀå °á¼® Áõ°¡¿Í °°Àº ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÁÖ·Î µðÀÚÀΰú Àç·áÀÇ °³¼±À» Æ÷ÇÔÇÑ ½ºÅÙÆ® ±â¼úÀÇ Çõ½ÅÀº ȯÀÚÀÇ ¾ÈÀü°ú Ä¡·á °á°ú¸¦ ¸ðµÎ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ ºñ´¢±â°ú Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡´Â ½ºÅÙÆ® ¼ö¿ä Áõ°¡¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ÇöÀúÇÑ °æÇâ°ú Ä¡·á ¹æ¹ý¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡´Â ½ÃÀåÀÇ ¼ºÀå µ¿·ÂÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ º¸±Þ°ú ½ÅÈï Áö¿ª¿¡¼­ °í±Þ ºñ´¢±â°ú ÀÇ·áÀÇ °¡¿ë¼º Çâ»óµµ ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹Àº ¼¼°è ¿ä°ü ½ºÅÙÆ® ½ÃÀå¿¡¼­ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÁÖ·Î Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó¿Í ½ÅÀå Áúȯ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ³ª¶ó´Â ź·ÂÀûÀÎ R&D ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÅëÇØ ¸¹Àº ÇýÅÃÀ» ´©¸®°í ÀÖÀ¸¸ç, ±× °á°ú ȯÀÚµéÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±Çϴ ÷´Ü ½ºÅÙÆ® ±â¼úÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ø»Ó¸¸ ¾Æ´Ï¶ó Àü¹® Ŭ¸®´ÐÀÇ ÅºÅºÇÑ ³×Æ®¿öÅ©°¡ ÀÌ·¯ÇÑ ÀåºñÀÇ È°¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½À ¼ö¼úÀÇ Á߿伺ÀÌ °¡¼ÓÈ­µÇ°í ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÀÇ ÁúÀ» Áß½ÃÇÏ°í ±ÔÁ¦¸¦ °­È­ÇÏ´Â °Íµµ ¹Ì±¹ ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿ä°ü ½ºÅÙÆ® ½ÃÀå µ¿Çâ:

ºñ´¢±â Áúȯ Áõ°¡

ÀÌ ½ÃÀåÀº ºñ´¢±â°ú ÁúȯÀÇ À¯º´·üÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó ´«¿¡ ¶ç°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÀå°á¼®Àº ¿ä·Î¿Í ½ÅÀå¿¡ °íÇü¹°ÀÌ Çü¼ºµÇ¾î ¿ä°üÀ» ¸·À½À¸·Î½á ¸¸¼ºÀûÀÎ ÅëÁõ°ú ½ÅÀå¿¡ ½É°¢ÇÑ ¼Õ»óÀ» ÃÊ·¡ÇÏ´Â ÈçÇÑ ºñ´¢±â ÁúȯÀ¸·Î, ±× »ç·Ê Áõ°¡°¡ ½ÃÀå È®´ë¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. º¸°í¿¡ µû¸£¸é, ½ÅÀå °á¼®Àº Àü ¼¼°èÀûÀ¸·Î ÈçÇÑ Áúº´À¸·Î Àα¸ÀÇ ¾à 12%°¡ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ °æ¿ì ¿ä°ü ½ºÅÙÆ®¸¦ »ç¿ëÇÏ¸é ¸·ÈûÀ» ¿ÏÈ­ÇÏ°í ¼Òº¯ÀÇ È帧À» ¿øÈ°ÇÏ°Ô ÇÏ¿© ȯÀÚ¿¡°Ô ¾Èµµ°¨À» ÁÖ°í ´õ ħ½ÀÀûÀÎ ½Ã¼úÀÇ Çʿ伺À» °¨¼Ò½ÃÄÑ ¿ä°ü ½ºÅÙÆ® ¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü¸³¼± ºñ´ëÁõ, ¿ä·Î °¨¿°, ¹æ±¤ ¹®Á¦ µî ºñ´¢±â°ú Áúȯ¿¡ °É¸®±â ½¬¿î °í·ÉÈ­ »çȸÀÇ ±Þ¼ÓÇÑ ¹ßÀüµµ ±× ¹è°æÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ¿ä°üÀÇ ÇÕº´Áõ°ú ¸·ÈûÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á¿Í Áø´Ü ¸ðµÎ¿¡ ½ºÅÙÆ®¸¦ »ç¿ëÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, ºñ´¢±â°ú Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í Áø´Ü ±â¼úÀÇ ±Þ¼ÓÇÑ Çõ½ÅÀº Á¶±â ¹ß°ß°ú Á¶±â °³ÀÔÀ¸·Î À̾îÁ® Á¦Ç° äÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

½ºÅÙÆ®ÀÇ »õ·Î¿î ±â¼ú ¹ßÀü

¿ä°ü ½ºÅÙÆ®ÀÇ È¿´ÉÀ» Çâ»ó½Ã۰í ȯÀÚÀÇ Æí¾ÈÇÔ°ú °á°ú¸¦ °³¼±ÇÏ´Â Áß¿äÇÑ ¹ßÀü°ú Çõ½Å¿¡ ÀÇÇØ ½ÃÀåÀÌ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±âÁ¸ÀÇ ½ºÅÙÆ®´Â ÀϹÝÀûÀ¸·Î »ýºÐÇØµÇÁö ¾Ê´Â Àç·á·Î Á¦Á¶µÇ¾î Á¦°Å¸¦ À§ÇØ Àç¼ö¼úÀÌ ÇÊ¿äÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó »ýºÐÇØ¼º ½ºÅÙÆ®°¡ »ç¿ëµÇ±â ½ÃÀÛÇß°í, ½Ã°£ÀÌ Áö³ª¸é ü³»¿¡¼­ ¼­¼­È÷ ¿ëÇØµÇ±â ¶§¹®¿¡ Á¦°Å ½Ã¼úÀÇ Çʿ伺ÀÌ ¾ø¾îÁö°í ȯÀÚÀÇ ºÒÆíÇÔµµ ÁÙ¾îµé°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¾à¹° ¿ëÃâ ±â¼úÀ» µµÀÔÇÏ¿© ¿ä°ü ³»·Î õõÈ÷ ¹æÃâµÇ´Â ¾à¹°·Î ÄÚÆÃµÈ ½ºÅÙÆ®´Â ¿°Áõ, °¨¿° µîÀÇ ÇÕº´Áõ ¿¹¹æ¿¡ µµ¿òÀ» ÁÖ¾î ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ°í ½ºÅÙÆ®ÀÇ Ä¡·á È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¶ÇÇÑ, 3Â÷¿ø(3D) ÇÁ¸°ÆÃ ±â¼úÀÇ ÅëÇÕÀº ½ºÅÙÆ® ¼³°è¸¦ Çõ½ÅÀûÀ¸·Î º¯È­½ÃÄÑ È¯ÀÚº° ÇØºÎÇÐÀû ±¸Á¶¿¡ ¸Â´Â ¸ÂÃãÇü ½ºÅÙÆ®¸¦ Á¦ÀÛÇÒ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á Âø¿ë°¨À» °³¼±Çϰí Àڱذú ºÒÆíÇÔÀ» °¨¼Ò½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀÔ´Ï´Ù. IMARC GroupÀÇ Á¶»ç º¸°í¼­¿¡ µû¸£¸é, ÇコÄÉ¾î ºÐ¾ßÀÇ ¼¼°è 3D ÇÁ¸°ÆÃ ½ÃÀåÀº 2024³â 34¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥ ½ÃÇà

¿ä°ü ½ºÅÙÆ® äÅÃÀ» Àå·ÁÇÏ´Â À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥ÀÇ ½ÃÇàÀº ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥Àº ÀÇ·á Á¢±Ù¼º, ȯÀÚ °á°ú, ºñ¿ë È¿À²¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÇÑ º¸°í¼­¿¡ µû¸£¸é, °ÉÇÁÇù·ÂȸÀÇ(GCC)ÀÇ ÀÇ·áºñ ÁöÃâÀº 2027³â±îÁö 1,355¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀ¸·Î ÀÎ½Ä °³¼± Ä·ÆäÀΰú ÇコÄɾî ÇÁ·Î±×·¥¿¡ ´ëÇÑ º¸Á¶±Ý Áö¿ø µî ȯÀڵ鿡°Ô ½ºÅÙÆ®ÀÇ Á¢±Ù¼ºÀ» ³ô¿© ºñ´¢±â°ú ÁúȯÀÇ Á¶±â Áø´Ü ¹× Ä¡·á¸¦ °¡´ÉÇϰÔÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á±â±â ºÐ¾ß ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ÀçÁ¤Àû ¿ì´ë ¹× º¸Á¶±ÝÀ» Á¦°øÇÏ´Â À¯¸®ÇÑ Á¤Ã¥µµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Å« ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¾÷µéÀº º¸´Ù È¿°úÀûÀÌ°í Æí¾ÈÇϸç ÃÖ¼Òħ½ÀÀûÀΠ÷´Ü ½ºÅÙÆ® °³¹ß¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â »õ·Î¿î ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϰí, ȯÀÚÀÇ ÇÊ¿ä¿Í ¼±È£µµ¿¡ µû¶ó ´Ù¾çÇÑ ½ºÅÙÆ® ¼±ÅñÇÀ» âÃâÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¿ä°ü ½ºÅÙÆ® ½ÃÀå ¿¹ÃøÀº ±â¼ú ¹ßÀü, ȯÀÚ ÀÎ½Ä Çâ»ó, Á¦Ç° °³¹ß ¹× Á¢±Ù¼ºÀ» °­È­ÇÏ´Â Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¿ä°ü ½ºÅÙÆ® ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

  • ¿ÀÇ¿£µå ½ºÅÙÆ®
  • Ŭ·ÎÁîµå ¿£µå ½ºÅÙÆ®
  • ´õºí J ½ºÅÙÆ®
  • ¸ÖƼ·çÇÁ ½ºÅÙÆ®

Á¦7Àå ½ÃÀå ³»¿ª : Àç·áº°

  • ¸ÞÅ»¸¯ ¿ä°ü ½ºÅÙÆ®
  • Æú¸®¸Ó ¿ä°ü ½ºÅÙÆ®
    • ÁÖ¿ä Á¾·ù
      • ½Ç¸®ÄÜ ½ºÅÙÆ®
      • Æú¸®¿ì·¹Åº ½ºÅÙÆ®
      • ÇÏÀ̺긮µå ½ºÅÙÆ®

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ½ÅÀå °á¼®
  • ½ÅÀå À̽Ä
  • Á¾¾ç
  • ¿ä½Ç±Ý
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°

  • º´¿ø¡¤Áø·á¼Ò
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Allium Medical Solutions Ltd.
    • B. Braun Melsungen AG
    • Biomerics
    • Boston Scientific Corporation
    • Becton Dickinson and Company
    • Coloplast Ltd.
    • Cook Group Incorporated
    • Medline Industries Inc.
    • Merit Medical Systems Inc.
    • Olympus Corporation
    • Teleflex Incorporated
KSM

The global ureteral stents market size was valued at USD 395.52 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 619.22 Million by 2033, exhibiting a CAGR of 5.06% during 2025-2033. North America currently dominates the market, holding a significant market share of over 36.9% in 2024. The growing prevalence of urological disorders, emerging technological advances in stent technology, and the implementation of favorable government policies encouraging the adoption of ureteral stents are some of the major factors contributing to the market growth.

The global ureteral stents market is majorly impacted by several major factors, encompassing the rising cases of kidney problems, especially urinary tract hindrances and kidney stones. Innovations in stent technology, mainly including upgraded designs and materials, improve both patient safety and outcomes. Furthermore, the accelerating senior population, which is more prone to urological disorders, supports the elevating requirement. Notable inclination towards minimally invasive procedures and magnifying awareness associated with treatment methodologies further aid market growth dynamics. In addition, proliferating healthcare infrastructure and increased availability of advanced urological care in emerging regions are also crucial drivers of the ureteral stents market.

The United States accounts for a substantial nation in the global ureteral stents market, chiefly propelled by well-established healthcare infrastructure and an escalated incidents of kidney disorders. The nation heavily profits from resilient research and development initiatives, resulting in an advanced stent technologies that significantly improve patient outcomes. In addition, a robust network of specialized clinics as well as hospitals fosters the utilization of such devices. For instance, as per industry reports, there are 31,748 clinics and 6,120 hospitals in the U.S. Besides, the accelerating emphasis on minimally invasive surgeries and enhanced patient awareness further impacts market expansion substantially. Robust emphasis on quality healthcare and bolstering regulatory aid also act as a critical factor in steering the ureteral stents market in the U.S.

Ureteral Stents Market Trends:

Growing Incidents of Urological Disorders

The market has been witnessing a notable influence, attributed due to the accelerating prevalence of urological issues. In addition, the proliferating cases of kidney stones is a common urological disorder marked by the formation of solid masses in the urinary tract or kidney that block the ureter, resulting in chronic pain and significant damage to kidney is impacting the market expansion. Reports indicate that kidney stones are a common condition globally, affecting approximately 12% of the population. Besides, the fueling deployment of ureteral stents in these cases to mitigate obstruction and facilitate urine flow, providing patients relief while lowering need for more invasive procedures is bolstering the global ureteral stents market growth. Furthermore, the rapid increase in aging population that is more susceptible to urological diseases, encompassing benign prostatic hyperplasia, urinary tract infections, and bladder issues. Such conditions can result in ureteral complications or blockages, demanding the utilization of stents for both therapeutic and diagnostic applications. Moreover, the enhanced awareness of urological disorders and rapid innovations in diagnostic techniques led to early detection and intervention, which is accelerating the product adoption.

Emerging Technological Advances in Stents

The market is driven by significant advancements and innovations improving the effectiveness of ureteral stents and enhancing patient comfort and outcomes. In addition, traditional stents are typically produced from non-biodegradable materials, requiring a second procedure for removal. It led to the adoption of biodegradable stents, gradually dissolving within the body over time, eliminating the need for removal procedures and reducing patient discomfort. Moreover, the incorporation of drug-eluting technology, stents coated with medications that can be slowly released into the ureter, helping to prevent complications such as inflammation or infections which minimizes side effects and enhances the stent's therapeutic effect representing another major growth-inducing factor. Besides this, the integration of three-dimensional (3D) printing technology transforms stent design and allows for the creation of custom-made stents tailored to a patient's unique anatomy which ensures a better fit, reducing irritation and discomfort, accelerating the market growth. The research report of the IMARC Group states that the global 3D printing in healthcare market reached USD 3.4 Billion in 2024.

Implementation of Favorable Government Policies

The implementation of favorable government policies encouraging the adoption of ureteral stents is influencing the market growth. These policies are improving healthcare accessibility, patient outcomes, and cost-effectiveness. As per a report, the healthcare expenditure in the Gulf Cooperation Council (GCC) is predicted to reach USD 135.5 Billion by 2027. In addition, government initiatives include awareness campaigns and subsidized healthcare programs, making stents accessible to patients, allowing early diagnosis and treatment of urological conditions which is influencing the market growth. Moreover, several favorable policies can provide financial incentives and grants for research and development (R&D) in the medical device sector, representing another major growth-inducing factor. Also, companies are investing in developing advanced stents that are more effective, comfortable, and minimally invasive, which is augmenting the market growth. Besides this, government initiatives are encouraging new market players to enter the market leading to numerous stent options, catering to several patient needs and preferences, thus accelerating the market growth. The ureteral stents market forecast indicates sustained growth, driven by technological advancements, increasing patient awareness, and supportive regulatory frameworks that enhance product development and accessibility.

Ureteral Stents Industry Segmentation:

Analysis by Product Type:

  • Open End Stents
  • Closed End Stents
  • Double J-Stent
  • Multiloop Stents

Double J-stent stands as the largest product type in the global market. Also known as a double-pigtail stent, is a specialized product design characterized by its unique shape, which resembles the letter J with two curled ends. In addition, the double J-stent shape is optimized for stability and efficacy while the curled ends serve as anchors, securing the stent in place within the ureter, and influencing the market growth. It minimizes the risk of migration, where the stent may shift or dislodge from its intended position and ensures that the stent effectively facilitates urine drainage from the kidney to the bladder, preventing complications associated with ureteral obstructions. Moreover, the double-pigtail shape reduces irritation and discomfort for patients and with improved patient comfort contributes to greater patient compliance and satisfaction, augmenting the market growth. Besides this, the double J-stent is employed in clinical scenarios, from managing kidney stones and post-operative care to treating ureteral strictures which makes it a preferred choice for urologists and healthcare providers facing several patient needs.

Analysis by Material:

  • Metallic Ureteral Stents
  • Polymer Ureteral Stents
    • Silicone Stents
    • Polyurethane Stents
    • Hybrid Stents

Polymer ureteral stents lead the market with around 65.0% of market share in 2024. Polymer ureteral stents offer excellent biocompatibility and are well-tolerated by the body, minimizing the risk of allergic reactions or adverse tissue responses which makes them suitable for numerous patients, including those with sensitivities to other materials. Moreover, polymer stents are highly flexible and can conform to the natural curvature of the ureter, allowing for a more comfortable placement procedure and reducing the risk of stent migration or discomfort for the patient which enables a better fit within the urinary tract, reducing the chances of irritation or obstruction. Additionally, polymer ureteral stents are available in various sizes and configurations to cater to individual patient needs which ensures that urologists can select the most appropriate stent for each case, considering factors including the patient's anatomy and the specific urological condition. According to ureteral stents market research, the demand for polymer-based stents is expected to remain strong due to their superior biocompatibility, flexibility, and customization options, enhancing patient outcomes and procedural efficiency.

Analysis by Application:

  • Kidney Stones
  • Kidney Transplantation
  • Tumors
  • Urinary Incontinence
  • Others

Kidney stones lead the market with around 37.8% of market share in 2024. Kidney stones, medically known as nephrolithiasis or renal calculi, are a widespread urological issue affecting millions of individuals. These small, hard mineral and salt deposits can form in the kidneys and, when they move into the ureter, cause excruciating pain and block urine flow. In addition, the rising product demand for alleviating pain and facilitating the passage of kidney stones by inserting a stent into the ureter to act as a conduit, keeping the ureter open, and allowing the stone to pass more comfortably is influencing the market growth. It reduces pain and minimizes the risk of complications such as infection or kidney damage associated with prolonged blockage. Additionally, the prevalence of kidney stones due to dietary habits, dehydration, and lifestyle choices is escalating the product demand for kidney stone management, contributing to the market growth. Moreover, advancements in stent technology improved the efficacy of stents in this application with the development of biodegradable stents, drug-eluting stents, and 3D-printed stents which are more patient-friendly and effective in facilitating the passage of kidney stones, representing another major growth-inducing factor.

Analysis by End Use:

  • Hospitals and Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

Hospital and clinics lead the market by end use as they serve as primary points of care for patients with urological issues. In addition, hospitals are equipped with advanced medical facilities and expert urologists, are well-positioned to provide comprehensive care, including the insertion and monitoring of stents, contributing to the market growth. Moreover, hospitals and clinics have the infrastructure and expertise to perform complex urological procedures, such as the insertion and removal of stents which often require specialized equipment and highly trained medical staff that hospitals and clinics can easily provide, representing another major growth-inducing factor. Apart from this, the availability of numerous stent types and sizes is essential in addressing several needs of patients. Hospitals and clinics typically maintain a comprehensive inventory of ureteral stents, allowing them to select the most appropriate stent for each patient's specific condition and anatomy.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest ureteral stents market share of 36.9%. The North American market is typically being impacted by the well-structured healthcare system that encourages both research efforts and innovations for medical devices. It is a hub for globally leading urological experts, medical institutions, and research centers, which bolsters a culture of steady enhancement, resulting in the implementation as well as formulation of upgraded treatments and technologies, enveloping ureteral stents. In addition, the amplifying cases of kidney diseases significantly fuels the need for ureteral stents across the region. For instance, according to a research article published in BMJ Journal, in December 2024, every 1 in 10 people in Canada suffers with chronic kidney diseases. Moreover, the strong emphasis on patient care and comfort among healthcare providers aligning with the advancements in stent technology to enhance patient outcomes, represents another major growth-inducing factor. Patients in North America have access to the latest and most advanced medical treatments and devices, including advanced stents. Along with this, North America's implementation of an enhanced regulatory framework ensures the safety and efficacy of medical devices, including ureteral stents, instilling confidence in healthcare professionals and patients regarding the reliability and performance of the products available in the market, propelling the market growth.

Key Regional Takeaways:

United States Ureteral Stents Market Analysis

In 2024, United States accounted for 87.90% of the market share in North America. The growth of the ureteral stents market in the United States is being driven by several key factors. The increasing prevalence of kidney stones and urological disorders, often linked to lifestyle factors such as poor dietary habits and inadequate hydration, is leading to a higher demand for ureteral stents. Approximately 11% of men and 6% of women in the U.S. experience kidney stones at least once in their lives, based on the research report. In line with this, advancements in minimally invasive (MI) surgical techniques are further supporting the market by enabling quicker and more effective procedures requiring stent placement. An aging population also plays a significant role, as older individuals are more prone to conditions like kidney stones, strictures, and other urological issues. Technological innovations, including biodegradable and drug-eluting stents, are enhancing patient outcomes and improving adoption among healthcare providers due to reduced complications and better functionality. Apart from this, the rising awareness among patients and healthcare professionals about the benefits of early diagnosis and treatment for urological conditions is contributing to the market growth. Additionally, the increasing healthcare spending and access to advanced medical facilities is impelling the market growth. The market is further supported by ongoing research and development (R&D) efforts by manufacturers to introduce stents with improved designs and materials, addressing concerns such as patient discomfort and stent-related infections.

Asia Pacific Ureteral Stents Market Analysis

The Asia Pacific ureteral stents market is experiencing significant growth because of a combination of demographic, healthcare, and technological factors. The rising occurrence of urological conditions, including urinary tract blockages and kidney stone formation, serves as a significant factor propelling growth. Factors like changing dietary habits, rising obesity rates, and a growing aging population contribute to the rising incidence of these conditions, creating a sustained demand for ureteral stents. According to the United Nations Population Fund, the India Ageing Report 2023 predicted that the population of individuals aged 80 and above will increase by nearly 279% from 2022 to 2050. In addition, the growing healthcare infrastructure across the region, especially in developing markets such as China, India, and Southeast Asian countries, is enhancing availability of sophisticated urological care. Besides this, governing agencies in the region are investing heavily in modernizing healthcare systems, making procedures involving ureteral stents more widely available and affordable. This growth is further bolstered by high income levels and increased health awareness among the population. Furthermore, innovations in ureteral stent technology, including the creation of biodegradable, self-expanding, and drug-releasing stents, are improving therapeutic results and increasing patient satisfaction. These advancements are becoming increasingly popular as they tackle challenges such as infection concerns and patient discomfort linked to conventional stents. Local and international manufacturers are actively engaging in research and development, which drives the availability of cutting-edge products in the market.

Europe Ureteral Stents Market Analysis

The ureteral stents market in Europe is driven by a combination of healthcare advancements, demographic shifts, and increasing incidence of urological conditions. One of the key drivers is the rising prevalence of kidney stones and urinary tract obstructions, often linked to sedentary lifestyles, dietary habits, and higher rates of obesity. The increasing age of Europe's population drives demand, as elderly individuals face a heightened likelihood of experiencing urological conditions that necessitate stent implementation. Reports indicate that on 1 January 2023, the EU's population was estimated at 448.8 Million, with over one-fifth (21.3%) being 65 years or older. Apart from this, innovations in technology, including eco-friendly stents, medication-coated stents, and enhanced stent designs aimed at minimizing discomfort and complications, are increasingly being adopted. These advancements are widely adopted across European countries due to their focus on improving patient outcomes and reducing hospital stays. Moreover, the well-established healthcare infrastructure in Europe plays a pivotal role in driving the market. Countries in the region have high standards of medical care and widespread access to advanced urological treatments. Additionally, robust reimbursement policies and healthcare funding in many European nations make these procedures more accessible, further boosting demand for ureteral stents. Overall, Europe's commitment to advancing healthcare technologies, coupled with a growing need for effective urological treatments, positions the ureteral stents market for steady growth in the coming years.

Latin America Ureteral Stents Market Analysis

There is a rise in the prevalence of urological conditions like kidney stones and urinary tract obstructions as they are linked to changing dietary habits, inadequate hydration, and higher obesity rates. The rising awareness of urological health, along with the benefits of early intervention, is catalyzing the demand for ureteral stents across the region. Additionally, the growing demand for ureteral stents among the geriatric population, as they are more prone to kidney diseases, is offering a favorable market outlook. Between 2000 and 2023, the percentage of elderly individuals (60 years and older) in Brazil's population nearly doubled, growing from 8.7% to 15.6%, as reported by the IBGE. In line with this, advancements in healthcare infrastructure, particularly in countries like Brazil, Mexico, and Argentina, are improving access to advanced medical technologies, including MI urological procedures that require stent placement. Additionally, the region's expanding medical tourism sector contributes to market growth, offering cost-effective treatments for international patients. Furthermore, technological innovations, such as biodegradable and drug-eluting stents, are being adopted to enhance patient outcomes and reduce complications.

Middle East and Africa Ureteral Stents Market Analysis

The ureteral stents market in the Middle East and Africa is driven by the rising prevalence of kidney stones and urological disorders, influenced by factors such as high rates of dehydration in arid climates and dietary patterns. The increasing awareness of urological health, coupled with the growing adoption of MI procedures, is propelling the market growth. In addition, the thriving medical tourism, especially in countries like Saudi Arabia, is supporting the market growth. As per the IMARC Group, the Saudi Arabia medical tourism market is projected to exhibit a CAGR of 22.72% during 2024-2032. Besides this, healthcare infrastructure improvements, particularly in the Gulf Cooperation Council (GCC) countries, are enhancing the access to advanced medical treatments. In line with this, governing agencies in the region are undertaking initiatives and private investments for modernizing healthcare facilities.

Competitive Landscape:

The market environment features a diverse array of significant participants, including both innovative startups and well-established manufacturers within the medical device sector. Key companies actively emphasize on advancements, manufacturing innovative stent designs and materials to significantly lower complications as well as improve patient comfort. Moreover, strategic acquisitions, collaborations, and mergers are highly prevalent as firms navigate to augment their market reach and product portfolios. For instance, in April 2024, UnivLabs Technologies signed an MoA with IIT Roorkee, India, to design as well as commercialize the patented ureteral stents technology developed by IIT researchers. This technology exhibits the biodegradable stents composed of polymeric materials that can be enzymatically degraded. In addition, organizations are allocating greater resources to research and development initiatives aimed at delivering stents with improved functionality and compatibility with biological systems. Quality assurance and regulatory adherence remain crucial factors impacting competition, as firms strive to address the strict healthcare policies. Overall, the market is transforming, with ongoing innovations bolstering competition as well as enhancing patient outcomes in urological care.

The report provides a comprehensive analysis of the competitive landscape in the ureteral stents market with detailed profiles of all major companies, including:

  • Allium Medical Solutions Ltd.
  • B. Braun Melsungen AG
  • Biomerics
  • Boston Scientific Corporation
  • Becton, Dickinson and Company
  • Coloplast Ltd.
  • Cook Group Incorporated
  • Medline Industries Inc.
  • Merit Medical Systems Inc.
  • Olympus Corporation
  • Teleflex Incorporated

Key Questions Answered in This Report

  • 1.What are ureteral stents?
  • 2.How big is the global ureteral stents market?
  • 3.What is the expected growth rate of the global ureteral stents market during 2025-2033?
  • 4.What are the key factors driving the global ureteral stents market?
  • 5.What is the leading segment of the global ureteral stents market based on the product type?
  • 6.What is the leading segment of the global ureteral stents market based on material?
  • 7.What is the leading segment of the global ureteral stents market based on application?
  • 8.What is the leading segment of the global ureteral stents market based on end use?
  • 9.What are the key regions in the global ureteral stents market?
  • 10.Who are the key players/companies in the global ureteral stents market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ureteral Stents Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Open End Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Closed End Stents
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Double J-Stents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Multiloop Stents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Material

  • 7.1 Metallic Ureteral Stents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymer Ureteral Stents
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Silicone Stents
      • 7.2.2.2 Polyurethane Stents
      • 7.2.2.3 Hybrid Stents
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Kidney Stones
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Kidney Transplantation
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Tumors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Urinary Incontinence
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End Use

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Centers (ASCs)
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Allium Medical Solutions Ltd.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 B. Braun Melsungen AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Biomerics
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Boston Scientific Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Becton Dickinson and Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Coloplast Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Cook Group Incorporated
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Medline Industries Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 SWOT Analysis
    • 15.3.9 Merit Medical Systems Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Olympus Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Teleflex Incorporated
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦